Cyclosporine A (CsA) is one of the most effective and widely used immunosuppressant drugs in solid-organ transplantation and autoimmune diseases. Despite the beneficial effects of CsA, its long-term clinical use is limited by the chronic nephrotoxic potential, which is characterized by stripped interstitial fibrosis, tubulointerstitial inflammation, tubular atrophy, and afferent arteriolar hyalinosis [1] [2] [3] . Nevertheless, the molecular mechanisms driving CsA-induced nephrotoxicity remain elusive.
Epithelial-mesenchymal transition (EMT) is a biological process by which polarized epithelial cells lose their cell-cell adhesion and acquire migratory and invasive properties characteristics of mesenchymal cells during embryogenesis, wound healing, fibrosis, and tumor metastasis [4] . More and more evidences show that EMT plays a pathogenic role in CsA-induced renal fibrosis [5] [6] [7] . Manipulating EMT genes could ameliorate renal damage and fibrosis and apparently delay the progression of CsA-induced chronic nephropathy [7, 8] . Slattery et al. [5] found that CsAinduced EMT in human renal proximal tubular epithelial cells through upregulating E2A proteins. Shin et al. [8] demonstrated that Nrf2 played a protective role against CsA-induced renal fibrosis by inhibiting EMT genes. Liu et al. [9] disclosed that Klotho significantly inhibited CsA-induced renal lesions by modulating EMT-associated proteins. Recently, EMT was reported to be a strong predictor of graft function decline in renal transplant recipients exposed to CsA [10] . Therefore, disclosing the signaling molecules responsible for the EMT process will aid in understanding CsA-induced renal damage and developing future therapeutics.
miRNAs have been shown to be associated with renal development, homeostasis, and physiological functions [11] [12] [13] [14] . Clinical and experimental animal studies demonstrate that aberrant miRNA expression has been implicated in the pathogenesis of various renal diseases through modulating the EMT process [11, 15, 16] . For example, both miR-29 and miR-200 families protect kidneys from fibrosis by suppressing ECM deposition and preventing EMT, respectively [15] . Conversely, miR-21, miR-200, and miR-29 have been shown to amplify TGF-b-induced EMT and promote renal fibrosis [16] . Considering the increasing evidence that miRNAs function in renal diseases, we speculated that miRNAs may participate in CsAinduced renal fibrosis.
Our current study, for the first time, identified miR181c as the most dramatically downregulated miRNA in CsA-treated human renal cells and human renal tissues. miR-181c overexpression greatly attenuated CsAinduced EMT in vitro. CsA-induced EMT gene changes, renal damage, and fibrosis in vivo were apparently diminished by miR-181c mimics. Thus, miR-181c may serve as a therapeutic agent to minimize CsAinduced renal fibrosis through suppressing EMT, which could effectively expand its clinical applications by offsetting its nephrotoxic potential.
Materials and methods

Cell culture and reagents
Immortalized human renal cells (HK2) were cultured in Dulbecco's modified Eagle's medium (DMEM, low glucose; Gibco, London, UK) supplemented with 10% fetal bovine serum, 100 UÁmL À1 penicillin, 100 lgÁmL À1 streptomycin, and 2 mM L-glutamine at 37°C in a humidified atmosphere of 5% CO 2 . CsA (Sigma, St. Louis, MO, USA) was dissolved in olive oil at the concentration of 10 mM as a stock and kept at À20°C.
Animals
All animal experiments were performed under the approval of Institutional Animal Care and Use Committee (IACUC) at the Fourth Military Medical University. Nrf2À/À mice (male, 8-week-old) were purchased from Shanghai Model Organisms Center, Inc (Shanghai, China). Mice were randomized into four groups (n = 8/group): [1] miR-Ctrl viruses plus vehicle [2] ; miR-Ctrl viruses plus CsA [3] ; miR181c viruses plus vehicle [4] ; miR-181c viruses plus CsA. Two hundred microlitres of miR-181c-expressing viruses (miR-181c) and control viruses (miR-Ctrl) were intravenously injected into Nrf2À/À mice every 3 days. Mice were then administered either olive oil (5 mLÁkg
À1
) or olive oil-suspended CsA (30 mgÁkg
) by gavage once a day for 2 weeks. Mice were anesthetized with 2-3% isoflurane. Plasma and renal tissues were collected for measurement of renal function and immunohistochemistry (IHC). Liver, spleen, heart, and renal tissues were collected to determine miR-181c expression.
Plasmids, siRNAs, and oligonucleotides miR-181c promoter [from À2000 to +150 bp with respect to the transcription start site (TSS) of the human MIR181C transcript (accession number NR_029613)] was amplified using HK2 genomic DNA and cloned into the pGL3 luciferase vector. Mutation in the Nrf2 binding site was made by the Quikchange Multi site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) using the primer pairs 5
0 -gatgctgtgtttttttttacgcggg-3 0 (forward) and 5 0 -cccgcgtaaaaaaaaacacagcatc-3 0 (reverse; the mutation sites were shown in bold). Nrf2 cDNA was cloned into the pcDNA3.1(+) plasmid containing three FLAG tags. The notch2 3 0 -UTR with or without the miR-181c binding site (WT or mutant) was amplified by PCR using HK2 cDNA as a template and cloned into the pGL3 luciferase vector. Primer sequences used for cloning are shown in Table S1 . Mature has-miR-181c mimic (miR-181c), inhibitor (antimiR-181c), and a scrambled control (miR-Ctrl) were synthesized by Invitrogen siRNA-2, 5 0 -GCGGCTTTGTCTTTGGATT-3 0 ; siRNA-3,
miR-181c lentivirus
The pri-miR-181c sequence was amplified from genomic DNA and cloned into the pGMLV-MA1 miRNA lentiviral vector (Shanghai Genomeditech Co. Ltd., Shanghai, China) using XhoI and BamHI restriction enzymes to generate pGMLV-MA1-miR-181c. HEK293T cells were seeded onto 10-cm plates at a density of 1 9 10 6 cells. pGMLV-MA1-miR-181c plasmids were cotransfected with virapower packaging mix, containing packaging plasmid pMDL-gp-RRE, pRSV-Rev, pCMV-VSVG, and so on, into 293T cells to produce the lentivirus using the HG transgene reagent (Genomeditech Co., Shanghai, China) according to the manufacturer's instruction. Twenty-four hours later, the transfection mixture was replaced with complete medium. Viral supernatants were collected for 3 days. On days 5, the supernatants were pooled together and filtered through 0.45-lm pore size filters. 
Microarray analysis
The miRCURY LNA TM miRNA Array system [KangChen Bio-tech (a service provider for Exiqon), Shanghai, China, Cat# 208504] was applied to identify differentially expressed miRNAs. Briefly, small RNAs were isolated from HK2 cells treated with or without CsA and labeled with Cy3 and Cy5, respectively, according to the manufacturer's instructions. The fluorescence signals were collected and converted to digital signals: Values for CsA and vehicle group were assessed as log 2 (signal Cy3/signal Cy5). Positive values of log 2 means upregulation, and negative values of log 2 means downregulation.
Determination of miR-181c level
Human and mouse miR-181c expression was measured according to the manufacturer's instructions using the miScript PCR System (QIAGEN, Valencia, CA, USA) which comprises miScript Reverse Transcription Kit, miScript SYBR Green PCR Kit, and miScript Primer Assay. PCR conditions were 3 min at 95°C, and 40 cycles of 10 s at 95°C and 30 s at 60°C. U6 RNA was used as an endogenous control for data normalization. Samples were run in triplicates.
Western blotting
Cells with the indicated treatment were harvested and lysed in a RIPA buffer containing 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, and 50 mM NaF. Hundred microgram protein lysates were separated with 12% SDS/PAGE gel and transferred onto nitrocellulose membrane. After blocking with 5% nonfat dried milk solution in washing buffer containing 10 mM Tris (pH 7.5), 50 mM NaCl, and 0.02% Tween 20 (TBST), membranes were incubated overnight at 4°C with antibodies. Rabbit polyclonal anti-E-cadherin (SC-7870), mouse polyclonal anti-a-tubulin (SC-53646), rabbit polyclonal anti-Nrf2 (SC-13032), and mouse monoclonal antiNotch2 (SC-100307) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal anti-SMA (ab15734) and rabbit polyclonal anti-Vimentin (ab71144) were purchased from Abcam (Cambridge, UK). After washing three times with TBST, membranes were incubated for 1 h with horseradish peroxidase-coupled secondary antibodies (1 : 1000 dilution; Santa Cruz Biotechnology) at room temperature. Signals were detected with the ECL kit (Amersham Pharmacia Biotech, Amersham, UK). The scanned images were quantified using Kodak Digital Science one-dimensional software (Eastman Kodak Co., New Haven, CT, USA).
ChIP
HK2 cells were seeded in 10-cm dishes and transfected with Nrf2 plasmids containing three FLAG tags (1 lg) for 24 h. After protein-RNA cross-linking with 1% formaldehyde, cells were lysed in a buffer containing 10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.1% NP-40, 50 mM NaF, 10 mM Na3VO4, 10 mM sodium pyrophosphate, 50 mM disodium glycerol phosphate, 10 nM okadaic acid, 0.2% VRC, and 100 UÁmL À1 RNasin. The lysed cells were centrifuged at 12 000 g for 10 min at 4°C. The supernatants were precleaned for 60 min at 4°C by using 5 lL of Protein-A Sepharose beads (BD Biosciences, San Jose, CA, USA). After centrifugation, the supernatant was incubated with 30 lg of unrelated antibody (IgG; Sigma) or anti-FLAG at 4°C for 60 min. After incubation, 5 lL of protein-A Sepharose beads was added to all tubes and incubated for a further 60 min at 4°C. The tubes were centrifuged at 12 000 g for 5 min, and the precipitated beads were washed with lysis buffer three times. The RNA in the immunoprecipitated complex and the RNA in the previously saved input fraction were released by reversing the cross-linking at 65°C for 2 h with 200 mM NaCl and 20 lg of proteinase K. The RNAs were extracted as described above. Specific primers used to detect the association between Nrf2 and the miR181c promoter was as below: 
H&E staining
Kidneys were fixed in 10% neutral buffered formalin, and a paraffin embedding was carried out. Tissue sections with 3-4 lm thickness were stained with hematoxylin and eosin for microscopic evaluation.
Masson's trichrome staining
Collagen deposition in tissue sections was determined by the development of blue color following Masson's trichrome staining. Histomorphometrical analysis was conducted in 1 mm 2 of prepared specimens. Three kidneys from individual animals in each group were used. Ten fields in one kidney sample were selected and quantified.
Serum creatinine level
Renal damage was evaluated by measuring serum creatinine levels. Blood was kept at room temperature for coagulation and centrifuged at 6000 g for 20 min. Serum creatinine concentration was determined using an enzymatic colorimetric method (Modular DPP system, Roche, Hamburg, Germany) and measured at 510 nm using a SpectraMax Ò M5 microplate reader.
Statistical analysis
Data are expressed as mean AE SEM from three independent experiments. Except as indicated otherwise, statistical analysis was performed using Student's t-test to assess differences between experimental groups. P < 0.05 was considered statistically significant.
Results
CsA inhibits miR-181c expression
Emerging evidences showed that CsA-induced renal fibrosis through acting on EMT [6, 7] . miRNAs have been found to play critical roles in the EMT process [15, 16] . Thus, we investigated if miRNAs participated in CsA-induced renal fibrosis. Human renal HK2 cells were treated with CsA and vehicle, and microarray analysis was applied to identify differentially expressed miRNAs. Following CsA treatment, 79 miRNAs were increased and 117 were decreased by 2-fold or more ( Fig. 1A and Table S2 ). Several lines of evidences previously showed that mesenchymal markers were upregulated upon CsA treatment [8, 9] . Considering the negative regulation of miRNAs on target genes, we postulate that the downregulated miRNAs may probably participate in CsA-induced EMT. Among them, miR-181c was the most dramatically altered one by CsA (Fig. 1A) . In accord with microarray data, we found that CsA inhibited miR-181c expression by 5.89-fold in HK2 cells as determined by RT-PCR (Fig. 1B) . Consistently, in CsA-damaged human renal tissues, the miR-181c level was apparently suppressed by 4.05-fold compared to the kidney biopsy sections from patients without CsA treatment (Fig. 1C) .
Downregulation of miR-181c by CsA is dependent on Nrf2
We next examined if CsA affected miR-181c transcription. As shown in Fig. 2A , the luciferase activities driven by miR-181c promoter were gradually decreased with increased doses of CsA. By analyzing the transcription factors potentially binding to the miR-181c promoter, we found that there are two nuclear factor E2-related factor 2 (Nrf2) binding sites positioned at 610 and 8879 bp upstream of the TSS of miR-181c (Fig. 2B) . It has been reported that CsA-induced renal fibrosis partially results from inhibition of Nrf2 [8] .
Similarly, we confirmed a decreased Nrf2 expression after CsA treatment of HK2 cells (Fig. S1 ). Therefore, we speculate that CsA may inhibit miR-181c expression via Nrf2.
To demonstrate this, we tested the miR181c promoter construct with mutation of Nrf2 binding site (Fig. 2B) . As expected, CsA greatly inhibited the luciferase activities of miR-181c promoter containing Nrf2 binding site (WT). However, CsA failed to affect the mutant promoter activity (Fig. 2C) . Next, Nrf2 was overexpressed or silenced in HK2 cells (Fig. S2) , and its effects on miR-181c expression were determined. As shown in Fig. 2D , Nrf2 dramatically activated miR-181c transcription (WT). However, the luciferase activities of its mutant were not altered by Nrf2. Nrf2 overexpression apparently increased miR181c levels, which were moderately decreased by Nrf2 knockdown (Fig. 2E) . To detect if Nrf2 binds the miR-181c promoter directly, ChIP was performed. As a positive control, Nrf2 enrichment on the human HIF1-a promoter was confirmed (Fig. 2F, lane 9-10) . Similarly, RT-PCR products of miR-181c promoter flanking the Nrf2 binding site were found by ChIP assay in Nrf2-overexpressing cells (Fig. 2F , lane 5-6), indicating a direct association between Nrf2 and miR181c promoter.
miR-181c is involved in CsA-induced EMT
It has been suggested that EMT contributes to CsAinduced renal damage and fibrosis [8, 9] . We postulated that miR-181c may participate in this process. HK2 cells were transfected with scrambled miRNA (miR-Ctrl), miR-181c mimics (miR-181c), or miR-181c inhibitors (anti-miR-181c), respectively, and treated or not with CsA. In miR-Ctrl transfected cells, following CsA treatment, the expression of epithelial adhesion molecule Ecadherin was decreased by 2.33-fold, whereas the levels of myofibroblast markers smooth muscle actin (SMA) and vimentin were enhanced by 1.59-and 2.23-fold, respectively ( Fig. 3B-D , column 2 vs 1). In the presence of miR-181c, CsA-induced EMT gene changes were apparently attenuated. The E-cadherin level was reduced by 1.31-fold, and SMA and vimentin expression were elevated by 1.33-and 1.71-fold upon CsA treatment ( Fig. 3B-D, column 4 vs 3) . Conversely, upon anti-miR-181c transfection, E-cadherin expression was moderately reduced and SMA and vimentin levels were apparently increased relative to the miR-Ctrl group (Fig. 3B-D , column 5 vs 1), indicating that inhibition of miR-181c induced a more mesenchymal phenotype. CsA treatment further aggravated the effect of antimiR-181c (Fig. 3B -D, column 6 vs 5).
miR-181c partially restores CsA-induced renal damage and fibrosis in Nrf2À/À mice Our preliminary data and those of others showed that Nrf2-deficient mice (Nrf2À/À) develop severe renal damage and fibrosis following CsA treatment [8] . Considering the function of Nrf2 in EMT and its positive regulation on miR-181c, we asked if miR-181c can ameliorate CsA-induced renal damage and fibrosis in Nrf2À/À mice in vivo. miR-181c lentivirus (miR-181c) and control lentivirus (miR-Ctrl) were intravenously injected into Nrf2À/À mice, and miR-181c expression was confirmed in several tissues, including kidney (Fig. S3 ). Mice were then administered vehicle (olive oil) or CsA (30 mgÁkg À1 , p.o.) once a day for 2 weeks.
H&E staining showed that CsA treatment induced severe renal damage, including epithelial necrosis and tubular damages (Fig. 4A) . However, in the presence of miR-181c, CsA-caused renal damage was apparently alleviated, characterized by decreased degenerative regions and abnormal tubules (Fig. 4A) . Consistently, Masson's trichrome staining demonstrated that the percentage of collagen fiber deposited regions was dramatically increased by 3.75-fold upon CsA treatment in miR-Ctrl group, but only by 1.94-fold in the miR-181c group (Fig. 4B,C) . Next, renal function was evaluated by examining serum creatinine levels. Compared with the miR-Ctrl group, miR-181c injection reduced the increase in serum creatinine levels following CsA treatment (Fig. 4D) . Finally, the effect of miR-181c on CsA-induced EMT gene change was determined in vivo. CsA treatment resulted in a great loss of E-cadherin and a dramatic increase of SMA and vimentin expression in the miR-Ctrl group (Fig. 4E and Fig. S4 ). Upon miR-181c injection, E-cadherin expression was enhanced and SMA and vimentin expression was inhibited. CsA-induced changes in the expression of EMT genes were reduced ( Fig. 4E and Fig. S4.) . Thus, our data indicate that miR-181c may counteract CsA-induced renal damage and fibrosis, in part, by suppressing the EMT process.
Notch2 is a potential target of miR-181c
To disclose the molecular mechanisms by which miR181c affects the EMT process, its potential targets were analyzed. We found that Notch2 3 0 -UTR includes one potential miR-181c target site conserved in humans and mice. Current evidence has demonstrated that Notch2 regulates the expression of several mesenchymal genes at the transcriptional level [17] . We postulated that the effect of miR-181c on the EMT process may be mediated by Notch2. We first proved that Notch2 protein levels in HK2 cells were elevated by CsA in a time-dependent manner ( Fig. 5A-B) . Next, luciferase reporter assay showed that miR-181c significantly inhibited the activity of the Notch2 3 0 -UTR dose dependently (Fig. 5C ). However, with the deletion of miR-181c binding site (mutant), miR-181c failed to inhibit the activity of Notch2 3 0 -UTR (Fig. 5C) . Furthermore, miR-181c mimics significantly inhibited Notch2 mRNA and protein levels, which were markedly increased by miR-181c inhibitors (Fig. 5D-F) .
Discussion
Epithelial-mesenchymal transition is characterized as the transformation of closely adhered epithelial cells into unanchored, elongated mesenchymal cells, which is a typical phenomenon during the development of fibrosis in various diseases [4] . Accumulating evidences show that tubulointerstitial fibrosis is an important Fig. 3 . miR-181c participates in CsA-induced EMT gene changes. (A) Western blotting was performed to detect protein level of EMT markers (E-cadherin for epithelia, SMA, and vimentin for myofibroblasts). HK2 cells were seeded in 6-well plates and transfected with 100 pmol of scrambled microRNA (miR-Ctrl), miR-181c mimics (miR-181c), or miR-181c inhibitors (anti-miR-181c), respectively, and then treated with CsA (10 lM). Tubulin was used as a loading control. Results presented here were representative of three different experiments. (B-D) Quantification of EMT gene levels. *P < 0.01, # P < 0.05 relative to vehicle.
event in the pathogenesis of CsA-induced nephrotoxicity, whereas its molecular mechanisms are less understood [1, 2] . Our current study, for the first time, demonstrated that miR-181c dramatically ameliorated CsA-induced renal injury by improvement of renal fibrosis through inhibiting EMT. miR-181c participates in several biological pathways including tumorgenesis, inflammation, nervous and immune system development, and the tissue differentiation [18] [19] [20] [21] [22] . However, its effect on renal function is not well elucidated. In this study, miR-181c greatly attenuated CsA-induced EMT in vitro and in vivo. In addition, miR-181c also apparently alleviated CsAcaused renal damage and fibrosis in vivo, strongly suggesting that miR-181c may play critical roles in EMTassociated biological processes. Our speculation was supported by increased evidences showing that miR181c inhibited morphology-related traits in several tumor models such as gastric cancer and neuroblastoma through affecting the EMT process [19, [23] [24] [25] . For example, miR-181c inhibited glioblastoma cell invasion, migration, and mesenchymal transition by targeting the TGF-b pathway [24] and miR-181c inhibited the migration and invasion of neuroblastoma cells by targeting Smad7 [25] .
125 I irradiation effectively suppressed invasion of gastric cancer cells by reactivating miR-181c [23] . Collectively, our study, combined with others, strongly suggests that miR-181c may participate in more profound physiological and pathological processes associated with EMT.
There are six members of the miR-181 family identified in the human genome [26] . Hsa-miR-181c and hsa-miR-181d are clustered together on chromosome 19 and are separated by 66 base pairs [26] . Bioinformatics analysis found that no protein coding genes were found in this chromosome region containing both miRNAs, which indicates that miR-181c and miR-181d are independently transcribed. By searching the transcription factor database, we find that there are two Nrf2 binding sites upstream of the TSS of miR-181c, positioned at 610 and 8879 bp, respectively. Nrf2 is a basic leucine zipper transcription factor that binds to antioxidant response elements (AREs) present in the promoter region of a number of genes encoding antioxidant and detoxifying enzymes [27] . Recent studies disclosed that Nrf2 also transcriptionally activates EMT-related genes, such as STAT3 and Snail [28, 29] . As expected, our study indeed verified that a Nrf2 binding site located at 610 bp is indispensable for CsA or Nrf2-mediated regulation of miR-181c. In addition, our unpublished data also demonstrated that Nrf2 upregulates miR-181d expression. The mature transcripts for miR-181c and miR-181d are highly homologous with only one base pair difference distinguishing them. The simultaneous transcriptional activation will undoubtedly reinforce their regulatory effect on target genes. Bioinformatics analysis predicts that Notch2 is a putative target of both miRNAs. Although we merely validated a negative post-transcriptional regulation of miR-181c on Notch2, it is very likely that miR181d regulates Notch2 expression similarly. Moreover, Notch2 3 0 -UTR shares 89% sequence identity in human and mouse, and the miR-181c binding site is highly conserved in both species, which strongly indicate that miR-181c-mediated negative regulation on Notch2 indeed exists in human, mouse, or other species. Therefore, miR-181c may well participate in Notch2-related biological functions, which needs to be further examined.
In addition to miR-181c, there are a series of miRNAs identified by microarray analysis to be regulated by CsA. For example, miR-34a and miR-200c, proved to play pivotal roles in EMT [30] [31] [32] , showed < 2-fold decrease by CsA. miR-34a plays an essential role against tumorigenesis and progression of cancer metastasis via inhibiting EMT in breast cancer, prostate cancer, ovarian cancer, and colorectal cancer [32, 33] . Its targets include EMT-inducing transcription factors, such as Twist1, Slug, ZEB1/2, and Notch [32, 34, 35] . miR-200c is one of the highly studied miRNAs in terms of development, stemness, EMT, therapy resistance, and metastasis [30] . Considering miR-200c functioning at the crossroad of EMT and a large variety of biological processes, especially drug resistance, chemoresistance, and radioresistance, miR-200c has been explored as a potential prognostic/diagnostic biomarker and therapeutics target in several diseases [30, 31] . Further study of CsAregulated miRNAs and the functions of their target genes will be of great significance to better understand the mechanisms of CsA-induced fibrosis.
In conclusion, we report here for the first time that a panel of miRNAs is regulated by CsA in human renal cells and that miR-181c is the most obviously downregulated miRNA. Importantly, our study shows that miR-181c markedly ameliorates CsA-induced renal damage and fibrosis in part through inhibiting EMT in vivo, thereby providing preliminary data to explore its potential therapeutic application in renal diseases in the future.
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